This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength
by Zacks Equity Research
Corcept (CORT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
by Zacks Equity Research
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 39.13% and 6.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
USANA Health Sciences (USNA) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -16.92% and 2.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
Navigate Market Turbulence With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Cool Company (CLCO), Corcept Therapeutics (CORT), TXO Partners (TXO), & JOYY (YY) are well-poised to gain.
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
by Zacks Equity Research
ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
by Zacks Equity Research
The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
by Zacks Equity Research
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
Select Medical (SEM) Expands Rehabilitation Services in Central PA
by Zacks Equity Research
Select Medical (SEM) and UPMC unveil a 20-bed satellite facility of Helen M. Simpson Rehabilitation Hospital in West Shore, thus enhancing specialized inpatient rehabilitation care in Central Pennsylvania.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
by Zacks Equity Research
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.